Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the same period last year. The growth was primarily driven by nearly $11 million in net sales of TONMYA, the company's flagship treatment for fibromyalgia. During the quarter, TONMYA generated 12,592 total prescriptions, a 100% sequential increase, with new patient prescriptions rising 36% and refills surging 207%.
The commercial performance of TONMYA is a critical indicator of its market acceptance and the company's ability to execute its launch strategy. Currently, TONMYA has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to expand to about 145 million lives once a managed Medicare agreement takes effect on January 1, 2027. The broadening access is likely to further boost prescription volumes and revenue in the coming quarters.
Beyond the commercial success, Tonix is advancing its clinical pipeline to diversify its portfolio. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder (MDD). Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These developments underscore Tonix's commitment to addressing high unmet medical needs in CNS and immunology.
The financial position of Tonix remains robust, with approximately $176.2 million in cash and cash equivalents at the end of the quarter. The company stated that its resources, along with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This provides a solid runway to support both commercial activities and ongoing research initiatives.
The strong revenue growth and pipeline progress highlight Tonix's transition into a fully-integrated, commercial-stage biotechnology company. TONMYA, a sublingual tablet formulation of cyclobenzaprine, represents the first new treatment for fibromyalgia in over 15 years, offering a new option for patients and physicians. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra, contributing to a diversified revenue stream.
Tonix's strategic focus on high-need areas is evidenced by its pipeline, which includes TNX-2900 for Prader-Willi syndrome and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection. These programs, alongside the ongoing Phase 2 trials for TONMYA in MDD and acute stress disorder, demonstrate the company's breadth and scientific depth.
For investors, the Q2 results provide confidence in Tonix's commercial execution and growth trajectory. The significant increase in prescriptions and revenue, combined with expanding payer coverage, positions TONMYA for continued success. The advancement of the pipeline further diversifies the company's risk and potential upside. As Tonix approaches key milestones, such as the January 2027 coverage expansion and the initiation of the Lyme disease study, the coming quarters will be pivotal in assessing long-term value.
For more information, visit the press release at https://nnw.fm/6Yytj.
